In the highest-security boardroom of Aetheris dical Holdings, tension crackled in the air like static electricity.
The ten most powerful pharmaceutical CEOs in Panterra gathered around a sleek black glass table, their faces illuminated by the cold glow of holographic schematics.
Displayed were the AMHP-9 Erald Rebirth Pod, VitaCore Erald Liquid, and alarming market-crash projections triggered by the NanoGel EM1 QuickPatch.
The atmosphere was thick with an unsettling mix of ozone and quiet panic.
As they sat there, it was clear: these leaders were not just business moguls; they were titans of an industry worth hundreds of trillions of Unicreds.
Yet today, their expressions betrayed a rare vulnerability, gloom etched into every furrowed brow, eyes glinting with icy resolve.
Darius Veyne, the venerable CEO of Aetheris dical Holdings and its oldest mber at nearly two centuries old, drumd a slow, ominous rhythm on the table.
His company had long dominated synthetic organ farming.
Across from him sat Lira Solmarr from NexGen BioSolutions, a razor-sharp strategist who had transford gene therapy into a multi-trillion Unicreds enterprise.
Her gaze remained fixed on the holographic screens displaying data that could reshape their futures.
Rook Kael from Pandora Health Systems shifted restlessly; his eyes flickered as he scanned Osborn's patent filings.
Senna Voss, the queen of rare disease monopolies, sat stoically with an expression that could freeze fire.
Talis Orin from BioVertex International looked ready to explode with rage; half the world's trauma clinics belonged to him.
Joran Dyre from Eclipse Therapeutics was a silent but heavy presence in the room, his reputation for involvent in black-market dical deals lood large over them all.
The youngest CEO present, Veyra Aldis from SynthLife Industries, typed rapidly into her data-slate.
While Korin Veyd from VitaForge Labs clenched his jaw tight enough to crack teeth over chronic pain managent subscriptions.
Mira Hel from Novadica appeared almost amused as she steepled her fingers under her chin like a spectator at a thrilling play.
And then there was Draven Sol from Obelisk Biotech, the ghostly figure whose influence perated every hospital contract despite never appearing on stock filings.
In the ever-evolving landscape of the pharmaceutical industry, a select group of ten companies reign supre, each boasting market values that soar into the hundreds of trillions of Unicreds.
Today, however, they gathered around a conference table with heavy hearts and furrowed brows.
The recent innovations from Osborn Pharmaceutical and Biotech Group have sent shockwaves through their ranks, causing countless smaller firms, especially those in skin reconstruction and regeneration,to crumble overnight.
Yet for these titans, this disruption isn't rely an inconvenience; it's a threat to their very existence.
As stock prices plumt, hundreds of billions of Unicreds evaporate into thin air.
While these giants view Osborn as just another blip on their radar, the reality is far more concerning.
The cutting-edge technologies developed by Osborn threaten to monopolize the skin reconstructive sector, a scenario that cannot be tolerated by those at the top.
The atmosphere in the room was thick with tension as everyone exchanged glances filled with apprehension.
Darius Veyne, CEO of Aetheris dical Holdings, broke the silence first. "Osborn has rendered forty percent of our combined product lines obsolete."
A hologram flickered to life, showcasing real-ti market data that painted a grim picture: demand for Aetheris' synthetic skin grafts had plumted by 68% within a week;
NexGen's nerve-repair serums were spiraling into freefall.
Pandora Health's military-grade burn treatnts were already facing inquiries about contract renegotiations from the Defense Ministry.
Senna Voss inhaled sharply. "We've faced disruptors before, we either buy them out or bury them in litigation."
Rook Kael interjected with visible concern, "Not this ti. Osborn's patents are airtight; their approvals flawless. And let's face it, the public adores them."
As murmurs filled the room like an impending storm cloud, Darius raised his voice above the din:
"We need counterasures, fast! If we don't act soon, Osborn will dominate the skin reconstructive sector."
"What do you suggest?" he pressed.
Talis Orin growled defiantly, "We can cut off their supply chains! No one sells them quantum-stabilized stem cells without our approval."
Darius shook his head firmly. "That won't work!"
"Why not?" Talis and others looked taken aback.
"Because," Darius replied while gesturing towards a new holographic display brimming with data, "Osborn has already secured their supply chain, they're well-prepared."
Mira Hel chid in with a charming smile that belied her concern. "Looks like they've done their howork!"
Lira Solmarr offered another suggestion: "What if we push a danger narrative? Leak reports about 'unstable nanite behavior' or fabricate adverse reactions?"
Darius shook his head and said,"No, the PHA has already publicly validated Osorn's safety data. Any fabricated claims would backfire spectacularly."
Veyra Aldis, her voice unnervingly calm, interjected, "We outpace them. Let's throw every Unicred we have at reverse-engineering their tech."
Jael sighed, shaking his head again. "We can do that, but it'll take a long ti. Preliminary reports suggest Osorn is at least five years ahead of industry standards."
Draven Sol leaned forward, his voice barely above a whisper yet charged with intensity. "We change the rules."
The room fell silent as his words hung in the air. "If we can't beat their science… we rewrite the laws governing it."
A slow, dark smile crept across Darius Veyne's face as he tapped his hands on the table and surveyed everyone in the room. "I've co up with a few plans that could help us!"
The rest of the team exchanged glances filled with curiosity and skepticism.
"Here's the plan:
Phase 1: We lobby the Panterran Health Authority to reclassify 'full-body cellular regeneration' as a high-risk procedure, necessitating impossible new safety checks.
Phase 2: We fund 'independent' research papers questioning VitaCore's long-term effects.
Phase 3:We approach Osborn Pharmaceutical and Biotech Group to explore investnt or even a buyout if they're willing.
Phase 4: (The Nuclear Option) If all else fails… we leak that Osorn's tech was reverse-engineered from off-world bioweapons."
Mira Hel finally broke into laughter. "You realize if this backfires, we all look like cartoon villains?"
Laughter erupted around the small conference room as they shared a mont of camaraderie amidst their scheming.
As their laughter faded into thoughtful silence, one thing beca clear: sotis you have to play dirty to win in a world where innovation is king.
----------------
The private elevator humd softly as it descended, its glass walls transitioning from transparent to opaque, signaling entry into Aetheris dical Holdings' most secure level.
Darius Veyne adjusted his cufflinks, catching a glimpse of himself in the polished steel doors,dark circles under his eyes hinted at countless sleepless nights since Osborn's shocking announcent.
As the doors slid open, a sterile chill enveloped him, and he stepped into the underground laboratory buzzing with frenetic activity.
The space was bathed in a cold blue glow from holographic displays, punctuated by the occasional flash of laser cutters at work.
His polished Oxfords clicked sharply against the antiseptic white floors as he strode forward.
"Status report," Veyne commanded, his voice slicing through the lab's chanical symphony like a knife.
Dr. Lina Voss looked up from the disassembled AMHP-9 pod, her usually pristine lab coat now marred with sothing that glowed faintly green.
"We've hit another wall," she admitted, tucking a loose strand of hair behind her ear with gloved fingers.
"The pod's neural interface doesn't just monitor, it learns. We tried running our standard diagnostic protocols and it..."
"It what?" Veyne leaned closer to inspect the pod's exposed interior, casting a shadow over its intricate latticework of bio-circuitry.
"It laughed at us," chid in a young technician from an adjacent workstation. At Veyne's sharp glance, he quickly corrected himself, "Figuratively speaking, sir. It adapted to bypass our scans before we could gather any aningful data."
Veyne's knuckles turned white as he gripped the edge of the examination table.
Across the lab, their military liaison, a square-jawed man with a cybernetic eye,was embroiled in an argunt with two researchers.
"You're telling this liquid can perfectly reconstruct tissue down to the capillary level, and you can't even identify all its components?"
The liaison's chanical eye whirred as it zood in on a holographic projection of VitaCore's molecular structure.
Dr. Kael, head of biochemical research, wiped sweat from his brow nervously. "We've isolated the base carrier fluid, a modified perfluorocarbon, but those nanobots? They're not just repairing damage; they're..." He hesitated for words.
"They're rewriting biology," Veyne finished quietly as he moved closer to a massive containnt unit where a single drop of VitaCore floated in zero-gravity suspension, pulsating with an eerie erald light.
Suddenly, a crash echoed through the lab as a junior researcher dropped a tray of instrunts near the NanoGel testing station.
"S-sorry!" he stamred while scrambling to clean up his ss.
Veyne's gaze drifted toward the isolation chamber, where their reverse-engineered version of NanoGel was undergoing a grim test.
Inside, the lab rat twitched helplessly, its paw grotesquely swollen and discolored from the imitation gel they had applied.
"Any progress?" he asked, though the answer hung heavy in the air like a dark cloud.
,
Reviews
All reviews (0)